Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...
Houston, Texas and Tuebingen, Germany, October 27, 2025 - Immatics N.V. (NASDAQ: IMTX, 'Immatics” or the 'Company”), a clinical-stage biopharmaceutical company and the global leader in precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback